Combined maintenance treatment of cancer patients responders to previous chemotherapy with immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents: clinical outcome, effects on cachexia symptoms, on proinflammatory cytokines and evaluation of quality of life